Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Heart Failure × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 250 Stomach Neoplasms 27 Neoplasm Metastasis 21 Neoplasms 15 Colorectal Neoplasms 13 Breast Neoplasms, Male 13 HER2-positive Breast Cancer 11 Triple Negative Breast Neoplasms 8 Esophageal Neoplasms 8 Inflammatory Breast Neoplasms 7 Rectal Neoplasms 6 Brain Neoplasms 6 Adenocarcinoma 6 Pathologic Complete Response 5 Colonic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Salivary Gland Neoplasms 4 Gallbladder Neoplasms 4 Biliary Tract Neoplasms 4 Urologic Neoplasms 3 Urinary Bladder Neoplasms 3 Recurrence 3 Cholangiocarcinoma 3 Carcinoma, Ductal, Breast 3 Sarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Neoplastic Cells, Circulating 2 Multiple Myeloma 2

Interventions

Control Groups 2 Atorvastatin 2 pertuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 Trastuzumab 1 Sodium Chloride 1 Simendan 1 Pyruvic Acid 1 Population Groups 1 Ogivri 1 Metoprolol 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Eplerenone 1 Carvedilol 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04680442 2025-04-06

SCHOLAR-2

Population Health Research Institute

Phase 2 Recruiting

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡